Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Amisulpride (Solian; Amazeo; Amipride; Amival; Soltus; Aminosultopride; DAN-2163; DAN2163; Deniban; Amisulprida; Sulpitac; Sulprix) is a potent and atypical antipsychotic medication used to treat psychosis in schizophrenia and episodes of mania in bipolar disorders. In Italy, it has also been utilized to treat dysthymia. With Ki values of 2.8±0.4nM for the D2 receptor subtype and 3.2±0.3nM for the D3 receptor subtype, respectively, amisulpride has demonstrated a strong affinity for the cloned and stably transfected human dopamine D2 receptor. It has been observed that amisulpride, with an IC50 value of 21nM, inhibits radioligand binding to native dopamine D2 receptor in rat striatal membranes.
Targets |
D2 Receptor ( IC50 = 2.8 nM ); D3 Receptor ( IC50 = 3.2 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
Amisulpride's functional effects at the dopamine D3 receptor subtype are evaluated. In summary, [3H]thymidine incorporation measures the mitogenic response induced in NG108-15 neuroblastoma-glioma cells stably transfected with human dopamine D3 receptor cDNA by adding 10 nM quinpirole in the presence of 1 μM forskolin. When Amisulpride concentrations increase from 0.1 to 100 nM, the antagonism of quinpirole-induced mitogenesis is measured[1].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C17H27N3O4S
|
|
---|---|---|
Molecular Weight |
369.48
|
|
Exact Mass |
369.17
|
|
Elemental Analysis |
C, 55.26; H, 7.37; N, 11.37; O, 17.32; S, 8.68
|
|
CAS # |
71675-85-9
|
|
Related CAS # |
Amisulpride-d5; 1216626-17-3; Amisulpride hydrochloride; 81342-13-4; Amisulpride-d5 N-Oxide; 1794756-15-2
|
|
Appearance |
Solid powder
|
|
SMILES |
CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
|
|
InChi Key |
NTJOBXMMWNYJFB-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
|
|
Chemical Name |
4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (6.77 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7065 mL | 13.5325 mL | 27.0651 mL | |
5 mM | 0.5413 mL | 2.7065 mL | 5.4130 mL | |
10 mM | 0.2707 mL | 1.3533 mL | 2.7065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04128683 | Active Recruiting |
Drug: amisulpride Drug: bromocriptine |
Anorexia Nervosa | University of California, San Diego | October 20, 2020 | Early Phase 1 |
NCT05956600 | Not yet recruiting | Drug: Amisulpride 50 MG | Schizophrenia, Treatment- Resistant |
University of California, Los Angeles |
November 2023 | Not Applicable |
NCT04341467 | Recruiting | Drug: Amisulpride Drug: Olanzapine |
BPSD Amisulpride |
Tianjin Anding Hospital | December 1, 2019 | Not Applicable |
NCT05822713 | Not yet recruiting | Drug: Amisulpride Drug: Amisulpride Placebo |
PONV | Qilu Pharmaceutical (Hainan) Co., Ltd. |
April 29, 2023 | Phase 3 |
NCT02926859 | Recruiting | Drug: Cannabidiol as add-on Drug: Placebo as add-on |
Schizophrenia | Central Institute of Mental Health, Mannheim |
Phase 2 | April 8, 2017 |